|
Market Closed -
Nasdaq
16:00:00 2026-11-20 EST
|
5-day change | 1st Jan Change | ||
| 1.660 USD | +4.40% |
|
+1.84% | -48.61% |
Business description: Alaunos Therapeutics, Inc.

Number of employees: 1
Sales by Activity: Alaunos Therapeutics, Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Biotechnology | 398K | 2.92M | 5K | 10K | 5K |
Geographical breakdown of sales: Alaunos Therapeutics, Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States | 398K | 2.92M | 5K | 10K | 5K |
Executive Committee: Alaunos Therapeutics, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Holger Weis
CEO | Chief Executive Officer | 63 | 2025-07-01 |
| Director of Finance/CFO | 42 | 2025-02-21 |
Composition of the Board of Directors: Alaunos Therapeutics, Inc.
| Director | Title | Age | Since |
|---|---|---|---|
Holger Weis
CHM | Chairman | 63 | 2023-09-21 |
Peter Harwin
BRD | Director/Board Member | 40 | 2026-10-12 |
Company details: Alaunos Therapeutics, Inc.

Bio Therapeutic Drugs
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +4.40% | +1.84% | - | - | 4.22M | ||
| -2.49% | -3.76% | +50.31% | +62.10% | 63.66B | ||
| -0.63% | -2.91% | +6.20% | +89.22% | 58.56B | ||
| -2.37% | -2.22% | +22.87% | +82.31% | 54.19B | ||
| -2.19% | -6.15% | +11.92% | +108.08% | 44.66B | ||
| -1.89% | -7.28% | +13.22% | +19.74% | 40.51B | ||
| -0.93% | -0.47% | +19.73% | +43.75% | 36.27B | ||
| +1.11% | -6.44% | +130.68% | +641.83% | 34.89B | ||
| -0.80% | +0.61% | +77.26% | +56.26% | 32.26B | ||
| -2.17% | +16.65% | -29.21% | +474.05% | 31.01B | ||
| Average | -0.80% | -0.91% | +33.67% | +175.26% | 40B | |
| Weighted average by Cap. | -1.48% | -1.85% | +32.16% | +150.90% |
Sector
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.660
Average target price
-
- Stock Market
- Stocks
- TCRT Stock
- Company Alaunos Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
















